SAM
TRVI icon

Smartleaf Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Smartleaf Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19 Hold
1
– – ﹤0.01% 3431
2026
Q1 		$11 Hold
1
– – ﹤0.01% 3486
2025
Q4 		$13 Hold
1
– – ﹤0.01% 3471
2025
Q3 		$8 Buy
+1
New +$7 ﹤0.01% 3000

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Smartleaf Asset Management's TRVI Position: Q2 2026 in Review

Smartleaf Asset Management held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 1 share worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Smartleaf Asset Management first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Smartleaf Asset Management held 1 share of Trevi Therapeutics worth $19 as of Q2 2026.
  • Smartleaf Asset Management left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3431 holding.
  • Smartleaf Asset Management first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.